<LCTL_TEXT lang="rus">
<DOC grammar="none" id="L0C04D4J6" lang="rus" raw_text_char_length="4694" raw_text_md5="31113d041bf2a88671d8f13c0ec6dd2a" tokenization="tokenization_parameters.v5.0">
<TEXT>
<SEG end_char="79" id="segment-0" start_char="1">
<ORIGINAL_TEXT>Regeneron сообщает о первых результатах КИ коктейля антител против коронавируса</ORIGINAL_TEXT>
<TOKEN end_char="9" id="token-0-0" morph="none" pos="word" start_char="1">Regeneron</TOKEN>
<TOKEN end_char="18" id="token-0-1" morph="none" pos="word" start_char="11">сообщает</TOKEN>
<TOKEN end_char="20" id="token-0-2" morph="none" pos="word" start_char="20">о</TOKEN>
<TOKEN end_char="27" id="token-0-3" morph="none" pos="word" start_char="22">первых</TOKEN>
<TOKEN end_char="39" id="token-0-4" morph="none" pos="word" start_char="29">результатах</TOKEN>
<TOKEN end_char="42" id="token-0-5" morph="none" pos="word" start_char="41">КИ</TOKEN>
<TOKEN end_char="51" id="token-0-6" morph="none" pos="word" start_char="44">коктейля</TOKEN>
<TOKEN end_char="59" id="token-0-7" morph="none" pos="word" start_char="53">антител</TOKEN>
<TOKEN end_char="66" id="token-0-8" morph="none" pos="word" start_char="61">против</TOKEN>
<TOKEN end_char="79" id="token-0-9" morph="none" pos="word" start_char="68">коронавируса</TOKEN>
<TRANSLATED_TEXT>Regeneron reports first results of CI cocktail antibodies against coronavirus</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="289" id="segment-1" start_char="83">
<ORIGINAL_TEXT>В пресс-релизе компании Regeneron Pharmaceuticals представлен описательный анализ первых результатов клинических испытаний эффективности коктейля антител REGN-COV2 против COVID-19 для амбулаторных пациентов.</ORIGINAL_TEXT>
<TOKEN end_char="83" id="token-1-0" morph="none" pos="word" start_char="83">В</TOKEN>
<TOKEN end_char="96" id="token-1-1" morph="none" pos="unknown" start_char="85">пресс-релизе</TOKEN>
<TOKEN end_char="105" id="token-1-2" morph="none" pos="word" start_char="98">компании</TOKEN>
<TOKEN end_char="115" id="token-1-3" morph="none" pos="word" start_char="107">Regeneron</TOKEN>
<TOKEN end_char="131" id="token-1-4" morph="none" pos="word" start_char="117">Pharmaceuticals</TOKEN>
<TOKEN end_char="143" id="token-1-5" morph="none" pos="word" start_char="133">представлен</TOKEN>
<TOKEN end_char="156" id="token-1-6" morph="none" pos="word" start_char="145">описательный</TOKEN>
<TOKEN end_char="163" id="token-1-7" morph="none" pos="word" start_char="158">анализ</TOKEN>
<TOKEN end_char="170" id="token-1-8" morph="none" pos="word" start_char="165">первых</TOKEN>
<TOKEN end_char="182" id="token-1-9" morph="none" pos="word" start_char="172">результатов</TOKEN>
<TOKEN end_char="194" id="token-1-10" morph="none" pos="word" start_char="184">клинических</TOKEN>
<TOKEN end_char="204" id="token-1-11" morph="none" pos="word" start_char="196">испытаний</TOKEN>
<TOKEN end_char="218" id="token-1-12" morph="none" pos="word" start_char="206">эффективности</TOKEN>
<TOKEN end_char="227" id="token-1-13" morph="none" pos="word" start_char="220">коктейля</TOKEN>
<TOKEN end_char="235" id="token-1-14" morph="none" pos="word" start_char="229">антител</TOKEN>
<TOKEN end_char="245" id="token-1-15" morph="none" pos="unknown" start_char="237">REGN-COV2</TOKEN>
<TOKEN end_char="252" id="token-1-16" morph="none" pos="word" start_char="247">против</TOKEN>
<TOKEN end_char="261" id="token-1-17" morph="none" pos="unknown" start_char="254">COVID-19</TOKEN>
<TOKEN end_char="265" id="token-1-18" morph="none" pos="word" start_char="263">для</TOKEN>
<TOKEN end_char="278" id="token-1-19" morph="none" pos="word" start_char="267">амбулаторных</TOKEN>
<TOKEN end_char="288" id="token-1-20" morph="none" pos="word" start_char="280">пациентов</TOKEN>
<TOKEN end_char="289" id="token-1-21" morph="none" pos="punct" start_char="289">.</TOKEN>
<TRANSLATED_TEXT>A press release from Regeneron Pharmaceuticals presents a descriptive analysis of the first results of clinical efficacy trials of REGN-COV2 anti-COVID-19 cocktail for outpatient patients.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="438" id="segment-2" start_char="291">
<ORIGINAL_TEXT>Согласно представленным данным, препарат наиболее целесообразно назначать серонегативным пациентам и пациентам с исходно высокой вирусной нагрузкой.</ORIGINAL_TEXT>
<TOKEN end_char="298" id="token-2-0" morph="none" pos="word" start_char="291">Согласно</TOKEN>
<TOKEN end_char="313" id="token-2-1" morph="none" pos="word" start_char="300">представленным</TOKEN>
<TOKEN end_char="320" id="token-2-2" morph="none" pos="word" start_char="315">данным</TOKEN>
<TOKEN end_char="321" id="token-2-3" morph="none" pos="punct" start_char="321">,</TOKEN>
<TOKEN end_char="330" id="token-2-4" morph="none" pos="word" start_char="323">препарат</TOKEN>
<TOKEN end_char="339" id="token-2-5" morph="none" pos="word" start_char="332">наиболее</TOKEN>
<TOKEN end_char="353" id="token-2-6" morph="none" pos="word" start_char="341">целесообразно</TOKEN>
<TOKEN end_char="363" id="token-2-7" morph="none" pos="word" start_char="355">назначать</TOKEN>
<TOKEN end_char="378" id="token-2-8" morph="none" pos="word" start_char="365">серонегативным</TOKEN>
<TOKEN end_char="388" id="token-2-9" morph="none" pos="word" start_char="380">пациентам</TOKEN>
<TOKEN end_char="390" id="token-2-10" morph="none" pos="word" start_char="390">и</TOKEN>
<TOKEN end_char="400" id="token-2-11" morph="none" pos="word" start_char="392">пациентам</TOKEN>
<TOKEN end_char="402" id="token-2-12" morph="none" pos="word" start_char="402">с</TOKEN>
<TOKEN end_char="410" id="token-2-13" morph="none" pos="word" start_char="404">исходно</TOKEN>
<TOKEN end_char="418" id="token-2-14" morph="none" pos="word" start_char="412">высокой</TOKEN>
<TOKEN end_char="427" id="token-2-15" morph="none" pos="word" start_char="420">вирусной</TOKEN>
<TOKEN end_char="437" id="token-2-16" morph="none" pos="word" start_char="429">нагрузкой</TOKEN>
<TOKEN end_char="438" id="token-2-17" morph="none" pos="punct" start_char="438">.</TOKEN>
<TRANSLATED_TEXT>It has been reported that the drug is most appropriate for seronegative patients and patients with baseline high viral load.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="585" id="segment-3" start_char="443">
<ORIGINAL_TEXT>Моноклональные антитела считаются перспективным средством для борьбы с COVID-19, и фармацевтические компании активно занимаются их разработкой.</ORIGINAL_TEXT>
<TOKEN end_char="456" id="token-3-0" morph="none" pos="word" start_char="443">Моноклональные</TOKEN>
<TOKEN end_char="465" id="token-3-1" morph="none" pos="word" start_char="458">антитела</TOKEN>
<TOKEN end_char="475" id="token-3-2" morph="none" pos="word" start_char="467">считаются</TOKEN>
<TOKEN end_char="489" id="token-3-3" morph="none" pos="word" start_char="477">перспективным</TOKEN>
<TOKEN end_char="499" id="token-3-4" morph="none" pos="word" start_char="491">средством</TOKEN>
<TOKEN end_char="503" id="token-3-5" morph="none" pos="word" start_char="501">для</TOKEN>
<TOKEN end_char="510" id="token-3-6" morph="none" pos="word" start_char="505">борьбы</TOKEN>
<TOKEN end_char="512" id="token-3-7" morph="none" pos="word" start_char="512">с</TOKEN>
<TOKEN end_char="521" id="token-3-8" morph="none" pos="unknown" start_char="514">COVID-19</TOKEN>
<TOKEN end_char="522" id="token-3-9" morph="none" pos="punct" start_char="522">,</TOKEN>
<TOKEN end_char="524" id="token-3-10" morph="none" pos="word" start_char="524">и</TOKEN>
<TOKEN end_char="541" id="token-3-11" morph="none" pos="word" start_char="526">фармацевтические</TOKEN>
<TOKEN end_char="550" id="token-3-12" morph="none" pos="word" start_char="543">компании</TOKEN>
<TOKEN end_char="558" id="token-3-13" morph="none" pos="word" start_char="552">активно</TOKEN>
<TOKEN end_char="569" id="token-3-14" morph="none" pos="word" start_char="560">занимаются</TOKEN>
<TOKEN end_char="572" id="token-3-15" morph="none" pos="word" start_char="571">их</TOKEN>
<TOKEN end_char="584" id="token-3-16" morph="none" pos="word" start_char="574">разработкой</TOKEN>
<TOKEN end_char="585" id="token-3-17" morph="none" pos="punct" start_char="585">.</TOKEN>
<TRANSLATED_TEXT>Monoclonal antibodies are considered a promising means of combating COVID-19, and pharmaceutical companies are actively developing them.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="694" id="segment-4" start_char="587">
<ORIGINAL_TEXT>16 сентября о промежуточных результатах клинических испытаний моноклонального антитела отчиталась Eli Lilly.</ORIGINAL_TEXT>
<TOKEN end_char="588" id="token-4-0" morph="none" pos="word" start_char="587">16</TOKEN>
<TOKEN end_char="597" id="token-4-1" morph="none" pos="word" start_char="590">сентября</TOKEN>
<TOKEN end_char="599" id="token-4-2" morph="none" pos="word" start_char="599">о</TOKEN>
<TOKEN end_char="613" id="token-4-3" morph="none" pos="word" start_char="601">промежуточных</TOKEN>
<TOKEN end_char="625" id="token-4-4" morph="none" pos="word" start_char="615">результатах</TOKEN>
<TOKEN end_char="637" id="token-4-5" morph="none" pos="word" start_char="627">клинических</TOKEN>
<TOKEN end_char="647" id="token-4-6" morph="none" pos="word" start_char="639">испытаний</TOKEN>
<TOKEN end_char="663" id="token-4-7" morph="none" pos="word" start_char="649">моноклонального</TOKEN>
<TOKEN end_char="672" id="token-4-8" morph="none" pos="word" start_char="665">антитела</TOKEN>
<TOKEN end_char="683" id="token-4-9" morph="none" pos="word" start_char="674">отчиталась</TOKEN>
<TOKEN end_char="687" id="token-4-10" morph="none" pos="word" start_char="685">Eli</TOKEN>
<TOKEN end_char="693" id="token-4-11" morph="none" pos="word" start_char="689">Lilly</TOKEN>
<TOKEN end_char="694" id="token-4-12" morph="none" pos="punct" start_char="694">.</TOKEN>
<TRANSLATED_TEXT>On September 16, Eli Lilly reported interim results of clinical trials of monoclonal antibodies.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="912" id="segment-5" start_char="696">
<ORIGINAL_TEXT>На этой неделе в сети появился пресс-релиз компании Regeneron Pharmaceuticals, в котором представлен описательный анализ первых данных, полученных в ходе фазы 1/2/3 клинических исследований коктейля антител REGN-COV2.</ORIGINAL_TEXT>
<TOKEN end_char="697" id="token-5-0" morph="none" pos="word" start_char="696">На</TOKEN>
<TOKEN end_char="702" id="token-5-1" morph="none" pos="word" start_char="699">этой</TOKEN>
<TOKEN end_char="709" id="token-5-2" morph="none" pos="word" start_char="704">неделе</TOKEN>
<TOKEN end_char="711" id="token-5-3" morph="none" pos="word" start_char="711">в</TOKEN>
<TOKEN end_char="716" id="token-5-4" morph="none" pos="word" start_char="713">сети</TOKEN>
<TOKEN end_char="725" id="token-5-5" morph="none" pos="word" start_char="718">появился</TOKEN>
<TOKEN end_char="737" id="token-5-6" morph="none" pos="unknown" start_char="727">пресс-релиз</TOKEN>
<TOKEN end_char="746" id="token-5-7" morph="none" pos="word" start_char="739">компании</TOKEN>
<TOKEN end_char="756" id="token-5-8" morph="none" pos="word" start_char="748">Regeneron</TOKEN>
<TOKEN end_char="772" id="token-5-9" morph="none" pos="word" start_char="758">Pharmaceuticals</TOKEN>
<TOKEN end_char="773" id="token-5-10" morph="none" pos="punct" start_char="773">,</TOKEN>
<TOKEN end_char="775" id="token-5-11" morph="none" pos="word" start_char="775">в</TOKEN>
<TOKEN end_char="783" id="token-5-12" morph="none" pos="word" start_char="777">котором</TOKEN>
<TOKEN end_char="795" id="token-5-13" morph="none" pos="word" start_char="785">представлен</TOKEN>
<TOKEN end_char="808" id="token-5-14" morph="none" pos="word" start_char="797">описательный</TOKEN>
<TOKEN end_char="815" id="token-5-15" morph="none" pos="word" start_char="810">анализ</TOKEN>
<TOKEN end_char="822" id="token-5-16" morph="none" pos="word" start_char="817">первых</TOKEN>
<TOKEN end_char="829" id="token-5-17" morph="none" pos="word" start_char="824">данных</TOKEN>
<TOKEN end_char="830" id="token-5-18" morph="none" pos="punct" start_char="830">,</TOKEN>
<TOKEN end_char="841" id="token-5-19" morph="none" pos="word" start_char="832">полученных</TOKEN>
<TOKEN end_char="843" id="token-5-20" morph="none" pos="word" start_char="843">в</TOKEN>
<TOKEN end_char="848" id="token-5-21" morph="none" pos="word" start_char="845">ходе</TOKEN>
<TOKEN end_char="853" id="token-5-22" morph="none" pos="word" start_char="850">фазы</TOKEN>
<TOKEN end_char="859" id="token-5-23" morph="none" pos="unknown" start_char="855">1/2/3</TOKEN>
<TOKEN end_char="871" id="token-5-24" morph="none" pos="word" start_char="861">клинических</TOKEN>
<TOKEN end_char="884" id="token-5-25" morph="none" pos="word" start_char="873">исследований</TOKEN>
<TOKEN end_char="893" id="token-5-26" morph="none" pos="word" start_char="886">коктейля</TOKEN>
<TOKEN end_char="901" id="token-5-27" morph="none" pos="word" start_char="895">антител</TOKEN>
<TOKEN end_char="911" id="token-5-28" morph="none" pos="unknown" start_char="903">REGN-COV2</TOKEN>
<TOKEN end_char="912" id="token-5-29" morph="none" pos="punct" start_char="912">.</TOKEN>
<TRANSLATED_TEXT>This week, Regeneron Pharmaceuticals released a press release describing the first data from phase 1 / 2 / 3 clinical trials of the REGN-COV2 antibody cocktail.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="1005" id="segment-6" start_char="914">
<ORIGINAL_TEXT>Компания планирует опубликовать детализированные результаты анализа в рецензируемом журнале.</ORIGINAL_TEXT>
<TOKEN end_char="921" id="token-6-0" morph="none" pos="word" start_char="914">Компания</TOKEN>
<TOKEN end_char="931" id="token-6-1" morph="none" pos="word" start_char="923">планирует</TOKEN>
<TOKEN end_char="944" id="token-6-2" morph="none" pos="word" start_char="933">опубликовать</TOKEN>
<TOKEN end_char="961" id="token-6-3" morph="none" pos="word" start_char="946">детализированные</TOKEN>
<TOKEN end_char="972" id="token-6-4" morph="none" pos="word" start_char="963">результаты</TOKEN>
<TOKEN end_char="980" id="token-6-5" morph="none" pos="word" start_char="974">анализа</TOKEN>
<TOKEN end_char="982" id="token-6-6" morph="none" pos="word" start_char="982">в</TOKEN>
<TOKEN end_char="996" id="token-6-7" morph="none" pos="word" start_char="984">рецензируемом</TOKEN>
<TOKEN end_char="1004" id="token-6-8" morph="none" pos="word" start_char="998">журнале</TOKEN>
<TOKEN end_char="1005" id="token-6-9" morph="none" pos="punct" start_char="1005">.</TOKEN>
<TRANSLATED_TEXT>The company plans to publish detailed results of the analysis in a peer-reviewed journal.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="1156" id="segment-7" start_char="1008">
<ORIGINAL_TEXT>REGN-COV2 — это комбинация двух нейтрализующих человеческих моноклональных антител (REGN10933 и REGN10987) к рецептор-связывающему домену SARS-CoV-2.</ORIGINAL_TEXT>
<TOKEN end_char="1016" id="token-7-0" morph="none" pos="unknown" start_char="1008">REGN-COV2</TOKEN>
<TOKEN end_char="1018" id="token-7-1" morph="none" pos="punct" start_char="1018">—</TOKEN>
<TOKEN end_char="1022" id="token-7-2" morph="none" pos="word" start_char="1020">это</TOKEN>
<TOKEN end_char="1033" id="token-7-3" morph="none" pos="word" start_char="1024">комбинация</TOKEN>
<TOKEN end_char="1038" id="token-7-4" morph="none" pos="word" start_char="1035">двух</TOKEN>
<TOKEN end_char="1053" id="token-7-5" morph="none" pos="word" start_char="1040">нейтрализующих</TOKEN>
<TOKEN end_char="1066" id="token-7-6" morph="none" pos="word" start_char="1055">человеческих</TOKEN>
<TOKEN end_char="1081" id="token-7-7" morph="none" pos="word" start_char="1068">моноклональных</TOKEN>
<TOKEN end_char="1089" id="token-7-8" morph="none" pos="word" start_char="1083">антител</TOKEN>
<TOKEN end_char="1091" id="token-7-9" morph="none" pos="punct" start_char="1091">(</TOKEN>
<TOKEN end_char="1100" id="token-7-10" morph="none" pos="word" start_char="1092">REGN10933</TOKEN>
<TOKEN end_char="1102" id="token-7-11" morph="none" pos="word" start_char="1102">и</TOKEN>
<TOKEN end_char="1112" id="token-7-12" morph="none" pos="word" start_char="1104">REGN10987</TOKEN>
<TOKEN end_char="1113" id="token-7-13" morph="none" pos="punct" start_char="1113">)</TOKEN>
<TOKEN end_char="1115" id="token-7-14" morph="none" pos="word" start_char="1115">к</TOKEN>
<TOKEN end_char="1137" id="token-7-15" morph="none" pos="unknown" start_char="1117">рецептор-связывающему</TOKEN>
<TOKEN end_char="1144" id="token-7-16" morph="none" pos="word" start_char="1139">домену</TOKEN>
<TOKEN end_char="1155" id="token-7-17" morph="none" pos="unknown" start_char="1146">SARS-CoV-2</TOKEN>
<TOKEN end_char="1156" id="token-7-18" morph="none" pos="punct" start_char="1156">.</TOKEN>
<TRANSLATED_TEXT>REGN-COV2 is a combination of two neutralizing human monoclonal antibodies (REGN10933 and REGN10987) to the SARS-CoV-2 receptor binding domain.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="1272" id="segment-8" start_char="1158">
<ORIGINAL_TEXT>При разработке препарата использовались гуманизированные мыши и антитела из крови пациентов, переболевших COVID-19.</ORIGINAL_TEXT>
<TOKEN end_char="1160" id="token-8-0" morph="none" pos="word" start_char="1158">При</TOKEN>
<TOKEN end_char="1171" id="token-8-1" morph="none" pos="word" start_char="1162">разработке</TOKEN>
<TOKEN end_char="1181" id="token-8-2" morph="none" pos="word" start_char="1173">препарата</TOKEN>
<TOKEN end_char="1196" id="token-8-3" morph="none" pos="word" start_char="1183">использовались</TOKEN>
<TOKEN end_char="1213" id="token-8-4" morph="none" pos="word" start_char="1198">гуманизированные</TOKEN>
<TOKEN end_char="1218" id="token-8-5" morph="none" pos="word" start_char="1215">мыши</TOKEN>
<TOKEN end_char="1220" id="token-8-6" morph="none" pos="word" start_char="1220">и</TOKEN>
<TOKEN end_char="1229" id="token-8-7" morph="none" pos="word" start_char="1222">антитела</TOKEN>
<TOKEN end_char="1232" id="token-8-8" morph="none" pos="word" start_char="1231">из</TOKEN>
<TOKEN end_char="1238" id="token-8-9" morph="none" pos="word" start_char="1234">крови</TOKEN>
<TOKEN end_char="1248" id="token-8-10" morph="none" pos="word" start_char="1240">пациентов</TOKEN>
<TOKEN end_char="1249" id="token-8-11" morph="none" pos="punct" start_char="1249">,</TOKEN>
<TOKEN end_char="1262" id="token-8-12" morph="none" pos="word" start_char="1251">переболевших</TOKEN>
<TOKEN end_char="1271" id="token-8-13" morph="none" pos="unknown" start_char="1264">COVID-19</TOKEN>
<TOKEN end_char="1272" id="token-8-14" morph="none" pos="punct" start_char="1272">.</TOKEN>
<TRANSLATED_TEXT>The drug was developed using humanized mice and antibodies from the blood of patients with COVID-19.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="1328" id="segment-9" start_char="1274">
<ORIGINAL_TEXT>Доклиническая оценка REGN-COV2 проводилась на приматах.</ORIGINAL_TEXT>
<TOKEN end_char="1286" id="token-9-0" morph="none" pos="word" start_char="1274">Доклиническая</TOKEN>
<TOKEN end_char="1293" id="token-9-1" morph="none" pos="word" start_char="1288">оценка</TOKEN>
<TOKEN end_char="1303" id="token-9-2" morph="none" pos="unknown" start_char="1295">REGN-COV2</TOKEN>
<TOKEN end_char="1315" id="token-9-3" morph="none" pos="word" start_char="1305">проводилась</TOKEN>
<TOKEN end_char="1318" id="token-9-4" morph="none" pos="word" start_char="1317">на</TOKEN>
<TOKEN end_char="1327" id="token-9-5" morph="none" pos="word" start_char="1320">приматах</TOKEN>
<TOKEN end_char="1328" id="token-9-6" morph="none" pos="punct" start_char="1328">.</TOKEN>
<TRANSLATED_TEXT>The pre-clinical evaluation of REGN-COV2 was performed on primates.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="1439" id="segment-10" start_char="1330">
<ORIGINAL_TEXT>Кроме того, было показано, что антитела Regeneron эффективно нейтрализуют вариант SARS-CoV-2 с мутацией D614G.</ORIGINAL_TEXT>
<TOKEN end_char="1334" id="token-10-0" morph="none" pos="word" start_char="1330">Кроме</TOKEN>
<TOKEN end_char="1339" id="token-10-1" morph="none" pos="word" start_char="1336">того</TOKEN>
<TOKEN end_char="1340" id="token-10-2" morph="none" pos="punct" start_char="1340">,</TOKEN>
<TOKEN end_char="1345" id="token-10-3" morph="none" pos="word" start_char="1342">было</TOKEN>
<TOKEN end_char="1354" id="token-10-4" morph="none" pos="word" start_char="1347">показано</TOKEN>
<TOKEN end_char="1355" id="token-10-5" morph="none" pos="punct" start_char="1355">,</TOKEN>
<TOKEN end_char="1359" id="token-10-6" morph="none" pos="word" start_char="1357">что</TOKEN>
<TOKEN end_char="1368" id="token-10-7" morph="none" pos="word" start_char="1361">антитела</TOKEN>
<TOKEN end_char="1378" id="token-10-8" morph="none" pos="word" start_char="1370">Regeneron</TOKEN>
<TOKEN end_char="1389" id="token-10-9" morph="none" pos="word" start_char="1380">эффективно</TOKEN>
<TOKEN end_char="1402" id="token-10-10" morph="none" pos="word" start_char="1391">нейтрализуют</TOKEN>
<TOKEN end_char="1410" id="token-10-11" morph="none" pos="word" start_char="1404">вариант</TOKEN>
<TOKEN end_char="1421" id="token-10-12" morph="none" pos="unknown" start_char="1412">SARS-CoV-2</TOKEN>
<TOKEN end_char="1423" id="token-10-13" morph="none" pos="word" start_char="1423">с</TOKEN>
<TOKEN end_char="1432" id="token-10-14" morph="none" pos="word" start_char="1425">мутацией</TOKEN>
<TOKEN end_char="1438" id="token-10-15" morph="none" pos="word" start_char="1434">D614G</TOKEN>
<TOKEN end_char="1439" id="token-10-16" morph="none" pos="punct" start_char="1439">.</TOKEN>
<TRANSLATED_TEXT>It has also been shown that Regeneron antibodies effectively neutralise the variant of SARS-CoV-2 with mutation D614G.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="1549" id="segment-11" start_char="1441">
<ORIGINAL_TEXT>Разработка REGN-COV2 частично финансируется Управлением биомедицинских исследований и разработок (BARDA) США.</ORIGINAL_TEXT>
<TOKEN end_char="1450" id="token-11-0" morph="none" pos="word" start_char="1441">Разработка</TOKEN>
<TOKEN end_char="1460" id="token-11-1" morph="none" pos="unknown" start_char="1452">REGN-COV2</TOKEN>
<TOKEN end_char="1469" id="token-11-2" morph="none" pos="word" start_char="1462">частично</TOKEN>
<TOKEN end_char="1483" id="token-11-3" morph="none" pos="word" start_char="1471">финансируется</TOKEN>
<TOKEN end_char="1495" id="token-11-4" morph="none" pos="word" start_char="1485">Управлением</TOKEN>
<TOKEN end_char="1510" id="token-11-5" morph="none" pos="word" start_char="1497">биомедицинских</TOKEN>
<TOKEN end_char="1523" id="token-11-6" morph="none" pos="word" start_char="1512">исследований</TOKEN>
<TOKEN end_char="1525" id="token-11-7" morph="none" pos="word" start_char="1525">и</TOKEN>
<TOKEN end_char="1536" id="token-11-8" morph="none" pos="word" start_char="1527">разработок</TOKEN>
<TOKEN end_char="1538" id="token-11-9" morph="none" pos="punct" start_char="1538">(</TOKEN>
<TOKEN end_char="1543" id="token-11-10" morph="none" pos="word" start_char="1539">BARDA</TOKEN>
<TOKEN end_char="1544" id="token-11-11" morph="none" pos="punct" start_char="1544">)</TOKEN>
<TOKEN end_char="1548" id="token-11-12" morph="none" pos="word" start_char="1546">США</TOKEN>
<TOKEN end_char="1549" id="token-11-13" morph="none" pos="punct" start_char="1549">.</TOKEN>
<TRANSLATED_TEXT>The development of REGN-COV2 is partially funded by the US Department of Biomedical Research and Development (BARDA).</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="1651" id="segment-12" start_char="1552">
<ORIGINAL_TEXT>Описательный анализ охватывает данные о первых 275 пациентах, включенных в клиническое исследование.</ORIGINAL_TEXT>
<TOKEN end_char="1563" id="token-12-0" morph="none" pos="word" start_char="1552">Описательный</TOKEN>
<TOKEN end_char="1570" id="token-12-1" morph="none" pos="word" start_char="1565">анализ</TOKEN>
<TOKEN end_char="1581" id="token-12-2" morph="none" pos="word" start_char="1572">охватывает</TOKEN>
<TOKEN end_char="1588" id="token-12-3" morph="none" pos="word" start_char="1583">данные</TOKEN>
<TOKEN end_char="1590" id="token-12-4" morph="none" pos="word" start_char="1590">о</TOKEN>
<TOKEN end_char="1597" id="token-12-5" morph="none" pos="word" start_char="1592">первых</TOKEN>
<TOKEN end_char="1601" id="token-12-6" morph="none" pos="word" start_char="1599">275</TOKEN>
<TOKEN end_char="1611" id="token-12-7" morph="none" pos="word" start_char="1603">пациентах</TOKEN>
<TOKEN end_char="1612" id="token-12-8" morph="none" pos="punct" start_char="1612">,</TOKEN>
<TOKEN end_char="1623" id="token-12-9" morph="none" pos="word" start_char="1614">включенных</TOKEN>
<TOKEN end_char="1625" id="token-12-10" morph="none" pos="word" start_char="1625">в</TOKEN>
<TOKEN end_char="1637" id="token-12-11" morph="none" pos="word" start_char="1627">клиническое</TOKEN>
<TOKEN end_char="1650" id="token-12-12" morph="none" pos="word" start_char="1639">исследование</TOKEN>
<TOKEN end_char="1651" id="token-12-13" morph="none" pos="punct" start_char="1651">.</TOKEN>
<TRANSLATED_TEXT>The descriptive analysis covers data on the first 275 patients included in the clinical study.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="1749" id="segment-13" start_char="1653">
<ORIGINAL_TEXT>У всех пациентов диагноз COVID-19 был подтвержден лабораторно, все пациенты лечились амбулаторно.</ORIGINAL_TEXT>
<TOKEN end_char="1653" id="token-13-0" morph="none" pos="word" start_char="1653">У</TOKEN>
<TOKEN end_char="1658" id="token-13-1" morph="none" pos="word" start_char="1655">всех</TOKEN>
<TOKEN end_char="1668" id="token-13-2" morph="none" pos="word" start_char="1660">пациентов</TOKEN>
<TOKEN end_char="1676" id="token-13-3" morph="none" pos="word" start_char="1670">диагноз</TOKEN>
<TOKEN end_char="1685" id="token-13-4" morph="none" pos="unknown" start_char="1678">COVID-19</TOKEN>
<TOKEN end_char="1689" id="token-13-5" morph="none" pos="word" start_char="1687">был</TOKEN>
<TOKEN end_char="1701" id="token-13-6" morph="none" pos="word" start_char="1691">подтвержден</TOKEN>
<TOKEN end_char="1713" id="token-13-7" morph="none" pos="word" start_char="1703">лабораторно</TOKEN>
<TOKEN end_char="1714" id="token-13-8" morph="none" pos="punct" start_char="1714">,</TOKEN>
<TOKEN end_char="1718" id="token-13-9" morph="none" pos="word" start_char="1716">все</TOKEN>
<TOKEN end_char="1727" id="token-13-10" morph="none" pos="word" start_char="1720">пациенты</TOKEN>
<TOKEN end_char="1736" id="token-13-11" morph="none" pos="word" start_char="1729">лечились</TOKEN>
<TOKEN end_char="1748" id="token-13-12" morph="none" pos="word" start_char="1738">амбулаторно</TOKEN>
<TOKEN end_char="1749" id="token-13-13" morph="none" pos="punct" start_char="1749">.</TOKEN>
<TRANSLATED_TEXT>In all patients, COVID-19 was confirmed by the laboratory and all patients were treated on an outpatient basis.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="1915" id="segment-14" start_char="1751">
<ORIGINAL_TEXT>56% участников имели латиноамериканское происхождение, 13% — африканское; 64% были отнесены к группе риска развития тяжелого COVID-19 как минимум по одному признаку.</ORIGINAL_TEXT>
<TOKEN end_char="1752" id="token-14-0" morph="none" pos="word" start_char="1751">56</TOKEN>
<TOKEN end_char="1753" id="token-14-1" morph="none" pos="punct" start_char="1753">%</TOKEN>
<TOKEN end_char="1764" id="token-14-2" morph="none" pos="word" start_char="1755">участников</TOKEN>
<TOKEN end_char="1770" id="token-14-3" morph="none" pos="word" start_char="1766">имели</TOKEN>
<TOKEN end_char="1789" id="token-14-4" morph="none" pos="word" start_char="1772">латиноамериканское</TOKEN>
<TOKEN end_char="1803" id="token-14-5" morph="none" pos="word" start_char="1791">происхождение</TOKEN>
<TOKEN end_char="1804" id="token-14-6" morph="none" pos="punct" start_char="1804">,</TOKEN>
<TOKEN end_char="1807" id="token-14-7" morph="none" pos="word" start_char="1806">13</TOKEN>
<TOKEN end_char="1808" id="token-14-8" morph="none" pos="punct" start_char="1808">%</TOKEN>
<TOKEN end_char="1810" id="token-14-9" morph="none" pos="punct" start_char="1810">—</TOKEN>
<TOKEN end_char="1822" id="token-14-10" morph="none" pos="word" start_char="1812">африканское</TOKEN>
<TOKEN end_char="1823" id="token-14-11" morph="none" pos="punct" start_char="1823">;</TOKEN>
<TOKEN end_char="1826" id="token-14-12" morph="none" pos="word" start_char="1825">64</TOKEN>
<TOKEN end_char="1827" id="token-14-13" morph="none" pos="punct" start_char="1827">%</TOKEN>
<TOKEN end_char="1832" id="token-14-14" morph="none" pos="word" start_char="1829">были</TOKEN>
<TOKEN end_char="1841" id="token-14-15" morph="none" pos="word" start_char="1834">отнесены</TOKEN>
<TOKEN end_char="1843" id="token-14-16" morph="none" pos="word" start_char="1843">к</TOKEN>
<TOKEN end_char="1850" id="token-14-17" morph="none" pos="word" start_char="1845">группе</TOKEN>
<TOKEN end_char="1856" id="token-14-18" morph="none" pos="word" start_char="1852">риска</TOKEN>
<TOKEN end_char="1865" id="token-14-19" morph="none" pos="word" start_char="1858">развития</TOKEN>
<TOKEN end_char="1874" id="token-14-20" morph="none" pos="word" start_char="1867">тяжелого</TOKEN>
<TOKEN end_char="1883" id="token-14-21" morph="none" pos="unknown" start_char="1876">COVID-19</TOKEN>
<TOKEN end_char="1887" id="token-14-22" morph="none" pos="word" start_char="1885">как</TOKEN>
<TOKEN end_char="1895" id="token-14-23" morph="none" pos="word" start_char="1889">минимум</TOKEN>
<TOKEN end_char="1898" id="token-14-24" morph="none" pos="word" start_char="1897">по</TOKEN>
<TOKEN end_char="1905" id="token-14-25" morph="none" pos="word" start_char="1900">одному</TOKEN>
<TOKEN end_char="1914" id="token-14-26" morph="none" pos="word" start_char="1907">признаку</TOKEN>
<TOKEN end_char="1915" id="token-14-27" morph="none" pos="punct" start_char="1915">.</TOKEN>
<TRANSLATED_TEXT>Fifty-six per cent of the participants were of Latin American origin, 13 per cent were African; 64 per cent were classified as at risk of developing the heavy COVID-19 for at least one reason.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="1985" id="segment-15" start_char="1917">
<ORIGINAL_TEXT>Средний возраст участников составил 44 года, 51% из них были женщины.</ORIGINAL_TEXT>
<TOKEN end_char="1923" id="token-15-0" morph="none" pos="word" start_char="1917">Средний</TOKEN>
<TOKEN end_char="1931" id="token-15-1" morph="none" pos="word" start_char="1925">возраст</TOKEN>
<TOKEN end_char="1942" id="token-15-2" morph="none" pos="word" start_char="1933">участников</TOKEN>
<TOKEN end_char="1951" id="token-15-3" morph="none" pos="word" start_char="1944">составил</TOKEN>
<TOKEN end_char="1954" id="token-15-4" morph="none" pos="word" start_char="1953">44</TOKEN>
<TOKEN end_char="1959" id="token-15-5" morph="none" pos="word" start_char="1956">года</TOKEN>
<TOKEN end_char="1960" id="token-15-6" morph="none" pos="punct" start_char="1960">,</TOKEN>
<TOKEN end_char="1963" id="token-15-7" morph="none" pos="word" start_char="1962">51</TOKEN>
<TOKEN end_char="1964" id="token-15-8" morph="none" pos="punct" start_char="1964">%</TOKEN>
<TOKEN end_char="1967" id="token-15-9" morph="none" pos="word" start_char="1966">из</TOKEN>
<TOKEN end_char="1971" id="token-15-10" morph="none" pos="word" start_char="1969">них</TOKEN>
<TOKEN end_char="1976" id="token-15-11" morph="none" pos="word" start_char="1973">были</TOKEN>
<TOKEN end_char="1984" id="token-15-12" morph="none" pos="word" start_char="1978">женщины</TOKEN>
<TOKEN end_char="1985" id="token-15-13" morph="none" pos="punct" start_char="1985">.</TOKEN>
<TRANSLATED_TEXT>The average age of participants was 44 years, of which 51 per cent were women.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="2134" id="segment-16" start_char="1987">
<ORIGINAL_TEXT>Целью анализа была оценка антивирусной активности REGN-COV2 и выявление пациентов с наиболее выраженной клинической выгодой от применения препарата.</ORIGINAL_TEXT>
<TOKEN end_char="1991" id="token-16-0" morph="none" pos="word" start_char="1987">Целью</TOKEN>
<TOKEN end_char="1999" id="token-16-1" morph="none" pos="word" start_char="1993">анализа</TOKEN>
<TOKEN end_char="2004" id="token-16-2" morph="none" pos="word" start_char="2001">была</TOKEN>
<TOKEN end_char="2011" id="token-16-3" morph="none" pos="word" start_char="2006">оценка</TOKEN>
<TOKEN end_char="2024" id="token-16-4" morph="none" pos="word" start_char="2013">антивирусной</TOKEN>
<TOKEN end_char="2035" id="token-16-5" morph="none" pos="word" start_char="2026">активности</TOKEN>
<TOKEN end_char="2045" id="token-16-6" morph="none" pos="unknown" start_char="2037">REGN-COV2</TOKEN>
<TOKEN end_char="2047" id="token-16-7" morph="none" pos="word" start_char="2047">и</TOKEN>
<TOKEN end_char="2057" id="token-16-8" morph="none" pos="word" start_char="2049">выявление</TOKEN>
<TOKEN end_char="2067" id="token-16-9" morph="none" pos="word" start_char="2059">пациентов</TOKEN>
<TOKEN end_char="2069" id="token-16-10" morph="none" pos="word" start_char="2069">с</TOKEN>
<TOKEN end_char="2078" id="token-16-11" morph="none" pos="word" start_char="2071">наиболее</TOKEN>
<TOKEN end_char="2089" id="token-16-12" morph="none" pos="word" start_char="2080">выраженной</TOKEN>
<TOKEN end_char="2101" id="token-16-13" morph="none" pos="word" start_char="2091">клинической</TOKEN>
<TOKEN end_char="2109" id="token-16-14" morph="none" pos="word" start_char="2103">выгодой</TOKEN>
<TOKEN end_char="2112" id="token-16-15" morph="none" pos="word" start_char="2111">от</TOKEN>
<TOKEN end_char="2123" id="token-16-16" morph="none" pos="word" start_char="2114">применения</TOKEN>
<TOKEN end_char="2133" id="token-16-17" morph="none" pos="word" start_char="2125">препарата</TOKEN>
<TOKEN end_char="2134" id="token-16-18" morph="none" pos="punct" start_char="2134">.</TOKEN>
<TRANSLATED_TEXT>The purpose of the analysis was to evaluate the antiviral activity of REGN-COV2 and to identify patients with the most significant clinical benefit from the use of the drug.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="2186" id="segment-17" start_char="2136">
<ORIGINAL_TEXT>Участники были рандомизированы в соотношении 1:1:1.</ORIGINAL_TEXT>
<TOKEN end_char="2144" id="token-17-0" morph="none" pos="word" start_char="2136">Участники</TOKEN>
<TOKEN end_char="2149" id="token-17-1" morph="none" pos="word" start_char="2146">были</TOKEN>
<TOKEN end_char="2165" id="token-17-2" morph="none" pos="word" start_char="2151">рандомизированы</TOKEN>
<TOKEN end_char="2167" id="token-17-3" morph="none" pos="word" start_char="2167">в</TOKEN>
<TOKEN end_char="2179" id="token-17-4" morph="none" pos="word" start_char="2169">соотношении</TOKEN>
<TOKEN end_char="2185" id="token-17-5" morph="none" pos="unknown" start_char="2181">1:1:1</TOKEN>
<TOKEN end_char="2186" id="token-17-6" morph="none" pos="punct" start_char="2186">.</TOKEN>
<TRANSLATED_TEXT>Participants were randomized at a 1: 1: 1 ratio.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="2300" id="segment-18" start_char="2188">
<ORIGINAL_TEXT>Они получали однократную инфузию 8 г или 2,4 г REGN-COV2 (высокая и низкая дозировка соответственно) или плацебо.</ORIGINAL_TEXT>
<TOKEN end_char="2190" id="token-18-0" morph="none" pos="word" start_char="2188">Они</TOKEN>
<TOKEN end_char="2199" id="token-18-1" morph="none" pos="word" start_char="2192">получали</TOKEN>
<TOKEN end_char="2211" id="token-18-2" morph="none" pos="word" start_char="2201">однократную</TOKEN>
<TOKEN end_char="2219" id="token-18-3" morph="none" pos="word" start_char="2213">инфузию</TOKEN>
<TOKEN end_char="2221" id="token-18-4" morph="none" pos="word" start_char="2221">8</TOKEN>
<TOKEN end_char="2223" id="token-18-5" morph="none" pos="word" start_char="2223">г</TOKEN>
<TOKEN end_char="2227" id="token-18-6" morph="none" pos="word" start_char="2225">или</TOKEN>
<TOKEN end_char="2231" id="token-18-7" morph="none" pos="unknown" start_char="2229">2,4</TOKEN>
<TOKEN end_char="2233" id="token-18-8" morph="none" pos="word" start_char="2233">г</TOKEN>
<TOKEN end_char="2243" id="token-18-9" morph="none" pos="unknown" start_char="2235">REGN-COV2</TOKEN>
<TOKEN end_char="2245" id="token-18-10" morph="none" pos="punct" start_char="2245">(</TOKEN>
<TOKEN end_char="2252" id="token-18-11" morph="none" pos="word" start_char="2246">высокая</TOKEN>
<TOKEN end_char="2254" id="token-18-12" morph="none" pos="word" start_char="2254">и</TOKEN>
<TOKEN end_char="2261" id="token-18-13" morph="none" pos="word" start_char="2256">низкая</TOKEN>
<TOKEN end_char="2271" id="token-18-14" morph="none" pos="word" start_char="2263">дозировка</TOKEN>
<TOKEN end_char="2286" id="token-18-15" morph="none" pos="word" start_char="2273">соответственно</TOKEN>
<TOKEN end_char="2287" id="token-18-16" morph="none" pos="punct" start_char="2287">)</TOKEN>
<TOKEN end_char="2291" id="token-18-17" morph="none" pos="word" start_char="2289">или</TOKEN>
<TOKEN end_char="2299" id="token-18-18" morph="none" pos="word" start_char="2293">плацебо</TOKEN>
<TOKEN end_char="2300" id="token-18-19" morph="none" pos="punct" start_char="2300">.</TOKEN>
<TRANSLATED_TEXT>They received a single infusion of 8 g or 2.4 g REGN-COV2 (high and low doses respectively) or placebo.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="2468" id="segment-19" start_char="2302">
<ORIGINAL_TEXT>Перед началом лечения все пациенты прошли тест на антитела к SARS-CoV-2 и в зависимости от его результатов были классифицированы как серопозитивные или серонегативные.</ORIGINAL_TEXT>
<TOKEN end_char="2306" id="token-19-0" morph="none" pos="word" start_char="2302">Перед</TOKEN>
<TOKEN end_char="2314" id="token-19-1" morph="none" pos="word" start_char="2308">началом</TOKEN>
<TOKEN end_char="2322" id="token-19-2" morph="none" pos="word" start_char="2316">лечения</TOKEN>
<TOKEN end_char="2326" id="token-19-3" morph="none" pos="word" start_char="2324">все</TOKEN>
<TOKEN end_char="2335" id="token-19-4" morph="none" pos="word" start_char="2328">пациенты</TOKEN>
<TOKEN end_char="2342" id="token-19-5" morph="none" pos="word" start_char="2337">прошли</TOKEN>
<TOKEN end_char="2347" id="token-19-6" morph="none" pos="word" start_char="2344">тест</TOKEN>
<TOKEN end_char="2350" id="token-19-7" morph="none" pos="word" start_char="2349">на</TOKEN>
<TOKEN end_char="2359" id="token-19-8" morph="none" pos="word" start_char="2352">антитела</TOKEN>
<TOKEN end_char="2361" id="token-19-9" morph="none" pos="word" start_char="2361">к</TOKEN>
<TOKEN end_char="2372" id="token-19-10" morph="none" pos="unknown" start_char="2363">SARS-CoV-2</TOKEN>
<TOKEN end_char="2374" id="token-19-11" morph="none" pos="word" start_char="2374">и</TOKEN>
<TOKEN end_char="2376" id="token-19-12" morph="none" pos="word" start_char="2376">в</TOKEN>
<TOKEN end_char="2388" id="token-19-13" morph="none" pos="word" start_char="2378">зависимости</TOKEN>
<TOKEN end_char="2391" id="token-19-14" morph="none" pos="word" start_char="2390">от</TOKEN>
<TOKEN end_char="2395" id="token-19-15" morph="none" pos="word" start_char="2393">его</TOKEN>
<TOKEN end_char="2407" id="token-19-16" morph="none" pos="word" start_char="2397">результатов</TOKEN>
<TOKEN end_char="2412" id="token-19-17" morph="none" pos="word" start_char="2409">были</TOKEN>
<TOKEN end_char="2429" id="token-19-18" morph="none" pos="word" start_char="2414">классифицированы</TOKEN>
<TOKEN end_char="2433" id="token-19-19" morph="none" pos="word" start_char="2431">как</TOKEN>
<TOKEN end_char="2448" id="token-19-20" morph="none" pos="word" start_char="2435">серопозитивные</TOKEN>
<TOKEN end_char="2452" id="token-19-21" morph="none" pos="word" start_char="2450">или</TOKEN>
<TOKEN end_char="2467" id="token-19-22" morph="none" pos="word" start_char="2454">серонегативные</TOKEN>
<TOKEN end_char="2468" id="token-19-23" morph="none" pos="punct" start_char="2468">.</TOKEN>
<TRANSLATED_TEXT>Prior to treatment, all patients were tested for antibodies to SARS-CoV-2 and were classified as either seropositive or seronegative depending on the outcome.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="2521" id="segment-20" start_char="2470">
<ORIGINAL_TEXT>Кроме того, была проведена оценка вирусной нагрузки.</ORIGINAL_TEXT>
<TOKEN end_char="2474" id="token-20-0" morph="none" pos="word" start_char="2470">Кроме</TOKEN>
<TOKEN end_char="2479" id="token-20-1" morph="none" pos="word" start_char="2476">того</TOKEN>
<TOKEN end_char="2480" id="token-20-2" morph="none" pos="punct" start_char="2480">,</TOKEN>
<TOKEN end_char="2485" id="token-20-3" morph="none" pos="word" start_char="2482">была</TOKEN>
<TOKEN end_char="2495" id="token-20-4" morph="none" pos="word" start_char="2487">проведена</TOKEN>
<TOKEN end_char="2502" id="token-20-5" morph="none" pos="word" start_char="2497">оценка</TOKEN>
<TOKEN end_char="2511" id="token-20-6" morph="none" pos="word" start_char="2504">вирусной</TOKEN>
<TOKEN end_char="2520" id="token-20-7" morph="none" pos="word" start_char="2513">нагрузки</TOKEN>
<TOKEN end_char="2521" id="token-20-8" morph="none" pos="punct" start_char="2521">.</TOKEN>
<TRANSLATED_TEXT>In addition, a viral load assessment was carried out.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="2721" id="segment-21" start_char="2524">
<ORIGINAL_TEXT>Авторы исследования отмечают, что серологический статус участников хорошо коррелировал с вирусной нагрузкой: у серопозитивных пациентов она была значительно ниже и быстро снижалась даже без лечения.</ORIGINAL_TEXT>
<TOKEN end_char="2529" id="token-21-0" morph="none" pos="word" start_char="2524">Авторы</TOKEN>
<TOKEN end_char="2542" id="token-21-1" morph="none" pos="word" start_char="2531">исследования</TOKEN>
<TOKEN end_char="2551" id="token-21-2" morph="none" pos="word" start_char="2544">отмечают</TOKEN>
<TOKEN end_char="2552" id="token-21-3" morph="none" pos="punct" start_char="2552">,</TOKEN>
<TOKEN end_char="2556" id="token-21-4" morph="none" pos="word" start_char="2554">что</TOKEN>
<TOKEN end_char="2571" id="token-21-5" morph="none" pos="word" start_char="2558">серологический</TOKEN>
<TOKEN end_char="2578" id="token-21-6" morph="none" pos="word" start_char="2573">статус</TOKEN>
<TOKEN end_char="2589" id="token-21-7" morph="none" pos="word" start_char="2580">участников</TOKEN>
<TOKEN end_char="2596" id="token-21-8" morph="none" pos="word" start_char="2591">хорошо</TOKEN>
<TOKEN end_char="2609" id="token-21-9" morph="none" pos="word" start_char="2598">коррелировал</TOKEN>
<TOKEN end_char="2611" id="token-21-10" morph="none" pos="word" start_char="2611">с</TOKEN>
<TOKEN end_char="2620" id="token-21-11" morph="none" pos="word" start_char="2613">вирусной</TOKEN>
<TOKEN end_char="2630" id="token-21-12" morph="none" pos="word" start_char="2622">нагрузкой</TOKEN>
<TOKEN end_char="2631" id="token-21-13" morph="none" pos="punct" start_char="2631">:</TOKEN>
<TOKEN end_char="2633" id="token-21-14" morph="none" pos="word" start_char="2633">у</TOKEN>
<TOKEN end_char="2648" id="token-21-15" morph="none" pos="word" start_char="2635">серопозитивных</TOKEN>
<TOKEN end_char="2658" id="token-21-16" morph="none" pos="word" start_char="2650">пациентов</TOKEN>
<TOKEN end_char="2662" id="token-21-17" morph="none" pos="word" start_char="2660">она</TOKEN>
<TOKEN end_char="2667" id="token-21-18" morph="none" pos="word" start_char="2664">была</TOKEN>
<TOKEN end_char="2679" id="token-21-19" morph="none" pos="word" start_char="2669">значительно</TOKEN>
<TOKEN end_char="2684" id="token-21-20" morph="none" pos="word" start_char="2681">ниже</TOKEN>
<TOKEN end_char="2686" id="token-21-21" morph="none" pos="word" start_char="2686">и</TOKEN>
<TOKEN end_char="2693" id="token-21-22" morph="none" pos="word" start_char="2688">быстро</TOKEN>
<TOKEN end_char="2703" id="token-21-23" morph="none" pos="word" start_char="2695">снижалась</TOKEN>
<TOKEN end_char="2708" id="token-21-24" morph="none" pos="word" start_char="2705">даже</TOKEN>
<TOKEN end_char="2712" id="token-21-25" morph="none" pos="word" start_char="2710">без</TOKEN>
<TOKEN end_char="2720" id="token-21-26" morph="none" pos="word" start_char="2714">лечения</TOKEN>
<TOKEN end_char="2721" id="token-21-27" morph="none" pos="punct" start_char="2721">.</TOKEN>
<TRANSLATED_TEXT>The authors of the study note that the serological status of the participants was well correlated with viral load: in seropositive patients, it was significantly lower and rapidly decreased even without treatment.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="2835" id="segment-22" start_char="2723">
<ORIGINAL_TEXT>У серонегативных участников вирусная нагрузка изначально была значительно выше и без лечения снижалась медленнее.</ORIGINAL_TEXT>
<TOKEN end_char="2723" id="token-22-0" morph="none" pos="word" start_char="2723">У</TOKEN>
<TOKEN end_char="2738" id="token-22-1" morph="none" pos="word" start_char="2725">серонегативных</TOKEN>
<TOKEN end_char="2749" id="token-22-2" morph="none" pos="word" start_char="2740">участников</TOKEN>
<TOKEN end_char="2758" id="token-22-3" morph="none" pos="word" start_char="2751">вирусная</TOKEN>
<TOKEN end_char="2767" id="token-22-4" morph="none" pos="word" start_char="2760">нагрузка</TOKEN>
<TOKEN end_char="2778" id="token-22-5" morph="none" pos="word" start_char="2769">изначально</TOKEN>
<TOKEN end_char="2783" id="token-22-6" morph="none" pos="word" start_char="2780">была</TOKEN>
<TOKEN end_char="2795" id="token-22-7" morph="none" pos="word" start_char="2785">значительно</TOKEN>
<TOKEN end_char="2800" id="token-22-8" morph="none" pos="word" start_char="2797">выше</TOKEN>
<TOKEN end_char="2802" id="token-22-9" morph="none" pos="word" start_char="2802">и</TOKEN>
<TOKEN end_char="2806" id="token-22-10" morph="none" pos="word" start_char="2804">без</TOKEN>
<TOKEN end_char="2814" id="token-22-11" morph="none" pos="word" start_char="2808">лечения</TOKEN>
<TOKEN end_char="2824" id="token-22-12" morph="none" pos="word" start_char="2816">снижалась</TOKEN>
<TOKEN end_char="2834" id="token-22-13" morph="none" pos="word" start_char="2826">медленнее</TOKEN>
<TOKEN end_char="2835" id="token-22-14" morph="none" pos="punct" start_char="2835">.</TOKEN>
<TRANSLATED_TEXT>In seronegative participants, the viral load was initially much higher and decreased more slowly without treatment.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="2989" id="segment-23" start_char="2838">
<ORIGINAL_TEXT>Применение REGN-COV2 способствовало более быстрому снижению вирусной нагрузки, при этом чем выше она была изначально, тем значительнее было ее снижение.</ORIGINAL_TEXT>
<TOKEN end_char="2847" id="token-23-0" morph="none" pos="word" start_char="2838">Применение</TOKEN>
<TOKEN end_char="2857" id="token-23-1" morph="none" pos="unknown" start_char="2849">REGN-COV2</TOKEN>
<TOKEN end_char="2872" id="token-23-2" morph="none" pos="word" start_char="2859">способствовало</TOKEN>
<TOKEN end_char="2878" id="token-23-3" morph="none" pos="word" start_char="2874">более</TOKEN>
<TOKEN end_char="2887" id="token-23-4" morph="none" pos="word" start_char="2880">быстрому</TOKEN>
<TOKEN end_char="2896" id="token-23-5" morph="none" pos="word" start_char="2889">снижению</TOKEN>
<TOKEN end_char="2905" id="token-23-6" morph="none" pos="word" start_char="2898">вирусной</TOKEN>
<TOKEN end_char="2914" id="token-23-7" morph="none" pos="word" start_char="2907">нагрузки</TOKEN>
<TOKEN end_char="2915" id="token-23-8" morph="none" pos="punct" start_char="2915">,</TOKEN>
<TOKEN end_char="2919" id="token-23-9" morph="none" pos="word" start_char="2917">при</TOKEN>
<TOKEN end_char="2924" id="token-23-10" morph="none" pos="word" start_char="2921">этом</TOKEN>
<TOKEN end_char="2928" id="token-23-11" morph="none" pos="word" start_char="2926">чем</TOKEN>
<TOKEN end_char="2933" id="token-23-12" morph="none" pos="word" start_char="2930">выше</TOKEN>
<TOKEN end_char="2937" id="token-23-13" morph="none" pos="word" start_char="2935">она</TOKEN>
<TOKEN end_char="2942" id="token-23-14" morph="none" pos="word" start_char="2939">была</TOKEN>
<TOKEN end_char="2953" id="token-23-15" morph="none" pos="word" start_char="2944">изначально</TOKEN>
<TOKEN end_char="2954" id="token-23-16" morph="none" pos="punct" start_char="2954">,</TOKEN>
<TOKEN end_char="2958" id="token-23-17" morph="none" pos="word" start_char="2956">тем</TOKEN>
<TOKEN end_char="2971" id="token-23-18" morph="none" pos="word" start_char="2960">значительнее</TOKEN>
<TOKEN end_char="2976" id="token-23-19" morph="none" pos="word" start_char="2973">было</TOKEN>
<TOKEN end_char="2979" id="token-23-20" morph="none" pos="word" start_char="2978">ее</TOKEN>
<TOKEN end_char="2988" id="token-23-21" morph="none" pos="word" start_char="2981">снижение</TOKEN>
<TOKEN end_char="2989" id="token-23-22" morph="none" pos="punct" start_char="2989">.</TOKEN>
<TRANSLATED_TEXT>The application of REGN-COV2 contributed to a faster reduction in viral load, and the higher it was initially, the greater the reduction.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="3036" id="segment-24" start_char="2991">
<ORIGINAL_TEXT>Так, при исходной концентрации вируса более 10</ORIGINAL_TEXT>
<TOKEN end_char="2993" id="token-24-0" morph="none" pos="word" start_char="2991">Так</TOKEN>
<TOKEN end_char="2994" id="token-24-1" morph="none" pos="punct" start_char="2994">,</TOKEN>
<TOKEN end_char="2998" id="token-24-2" morph="none" pos="word" start_char="2996">при</TOKEN>
<TOKEN end_char="3007" id="token-24-3" morph="none" pos="word" start_char="3000">исходной</TOKEN>
<TOKEN end_char="3020" id="token-24-4" morph="none" pos="word" start_char="3009">концентрации</TOKEN>
<TOKEN end_char="3027" id="token-24-5" morph="none" pos="word" start_char="3022">вируса</TOKEN>
<TOKEN end_char="3033" id="token-24-6" morph="none" pos="word" start_char="3029">более</TOKEN>
<TOKEN end_char="3036" id="token-24-7" morph="none" pos="word" start_char="3035">10</TOKEN>
<TRANSLATED_TEXT>For example, at baseline virus concentrations greater than 10</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="3039" id="segment-25" start_char="3039">
<ORIGINAL_TEXT>5</ORIGINAL_TEXT>
<TOKEN end_char="3039" id="token-25-0" morph="none" pos="word" start_char="3039">5</TOKEN>
</SEG>
<SEG end_char="3173" id="segment-26" start_char="3042">
<ORIGINAL_TEXT>копий вирусных геномов на мл вирусная нагрузка в течение 7 дней снижалась на 50–60% по сравнению с плацебо-группой, при более чем 10</ORIGINAL_TEXT>
<TOKEN end_char="3046" id="token-26-0" morph="none" pos="word" start_char="3042">копий</TOKEN>
<TOKEN end_char="3055" id="token-26-1" morph="none" pos="word" start_char="3048">вирусных</TOKEN>
<TOKEN end_char="3063" id="token-26-2" morph="none" pos="word" start_char="3057">геномов</TOKEN>
<TOKEN end_char="3066" id="token-26-3" morph="none" pos="word" start_char="3065">на</TOKEN>
<TOKEN end_char="3069" id="token-26-4" morph="none" pos="word" start_char="3068">мл</TOKEN>
<TOKEN end_char="3078" id="token-26-5" morph="none" pos="word" start_char="3071">вирусная</TOKEN>
<TOKEN end_char="3087" id="token-26-6" morph="none" pos="word" start_char="3080">нагрузка</TOKEN>
<TOKEN end_char="3089" id="token-26-7" morph="none" pos="word" start_char="3089">в</TOKEN>
<TOKEN end_char="3097" id="token-26-8" morph="none" pos="word" start_char="3091">течение</TOKEN>
<TOKEN end_char="3099" id="token-26-9" morph="none" pos="word" start_char="3099">7</TOKEN>
<TOKEN end_char="3104" id="token-26-10" morph="none" pos="word" start_char="3101">дней</TOKEN>
<TOKEN end_char="3114" id="token-26-11" morph="none" pos="word" start_char="3106">снижалась</TOKEN>
<TOKEN end_char="3117" id="token-26-12" morph="none" pos="word" start_char="3116">на</TOKEN>
<TOKEN end_char="3123" id="token-26-13" morph="none" pos="unknown" start_char="3119">50–60</TOKEN>
<TOKEN end_char="3124" id="token-26-14" morph="none" pos="punct" start_char="3124">%</TOKEN>
<TOKEN end_char="3127" id="token-26-15" morph="none" pos="word" start_char="3126">по</TOKEN>
<TOKEN end_char="3137" id="token-26-16" morph="none" pos="word" start_char="3129">сравнению</TOKEN>
<TOKEN end_char="3139" id="token-26-17" morph="none" pos="word" start_char="3139">с</TOKEN>
<TOKEN end_char="3155" id="token-26-18" morph="none" pos="unknown" start_char="3141">плацебо-группой</TOKEN>
<TOKEN end_char="3156" id="token-26-19" morph="none" pos="punct" start_char="3156">,</TOKEN>
<TOKEN end_char="3160" id="token-26-20" morph="none" pos="word" start_char="3158">при</TOKEN>
<TOKEN end_char="3166" id="token-26-21" morph="none" pos="word" start_char="3162">более</TOKEN>
<TOKEN end_char="3170" id="token-26-22" morph="none" pos="word" start_char="3168">чем</TOKEN>
<TOKEN end_char="3173" id="token-26-23" morph="none" pos="word" start_char="3172">10</TOKEN>
<TRANSLATED_TEXT>copies of viral genomes per ml viral load was reduced by 50-60% over 7 days compared with the placebo group, with more than 10</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="3176" id="segment-27" start_char="3176">
<ORIGINAL_TEXT>6</ORIGINAL_TEXT>
<TOKEN end_char="3176" id="token-27-0" morph="none" pos="word" start_char="3176">6</TOKEN>
</SEG>
<SEG end_char="3213" id="segment-28" start_char="3179">
<ORIGINAL_TEXT>копий/мл — на 95%, при более чем 10</ORIGINAL_TEXT>
<TOKEN end_char="3186" id="token-28-0" morph="none" pos="unknown" start_char="3179">копий/мл</TOKEN>
<TOKEN end_char="3188" id="token-28-1" morph="none" pos="punct" start_char="3188">—</TOKEN>
<TOKEN end_char="3191" id="token-28-2" morph="none" pos="word" start_char="3190">на</TOKEN>
<TOKEN end_char="3194" id="token-28-3" morph="none" pos="word" start_char="3193">95</TOKEN>
<TOKEN end_char="3196" id="token-28-4" morph="none" pos="punct" start_char="3195">%,</TOKEN>
<TOKEN end_char="3200" id="token-28-5" morph="none" pos="word" start_char="3198">при</TOKEN>
<TOKEN end_char="3206" id="token-28-6" morph="none" pos="word" start_char="3202">более</TOKEN>
<TOKEN end_char="3210" id="token-28-7" morph="none" pos="word" start_char="3208">чем</TOKEN>
<TOKEN end_char="3213" id="token-28-8" morph="none" pos="word" start_char="3212">10</TOKEN>
<TRANSLATED_TEXT>95% copies / ml at more than 10</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="3216" id="segment-29" start_char="3216">
<ORIGINAL_TEXT>7</ORIGINAL_TEXT>
<TOKEN end_char="3216" id="token-29-0" morph="none" pos="word" start_char="3216">7</TOKEN>
</SEG>
<SEG end_char="3236" id="segment-30" start_char="3219">
<ORIGINAL_TEXT>копий/мл — на 99%.</ORIGINAL_TEXT>
<TOKEN end_char="3226" id="token-30-0" morph="none" pos="unknown" start_char="3219">копий/мл</TOKEN>
<TOKEN end_char="3228" id="token-30-1" morph="none" pos="punct" start_char="3228">—</TOKEN>
<TOKEN end_char="3231" id="token-30-2" morph="none" pos="word" start_char="3230">на</TOKEN>
<TOKEN end_char="3234" id="token-30-3" morph="none" pos="word" start_char="3233">99</TOKEN>
<TOKEN end_char="3236" id="token-30-4" morph="none" pos="punct" start_char="3235">%.</TOKEN>
<TRANSLATED_TEXT>99%.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="3447" id="segment-31" start_char="3239">
<ORIGINAL_TEXT>Медианное время до улучшения клинического состояния (до мягкого проявления симптомов или их отсутствия) составило 13 дней в плацебо-группе, 8 дней в группе высокой дозировки и 6 дней в группе низкой дозировки.</ORIGINAL_TEXT>
<TOKEN end_char="3247" id="token-31-0" morph="none" pos="word" start_char="3239">Медианное</TOKEN>
<TOKEN end_char="3253" id="token-31-1" morph="none" pos="word" start_char="3249">время</TOKEN>
<TOKEN end_char="3256" id="token-31-2" morph="none" pos="word" start_char="3255">до</TOKEN>
<TOKEN end_char="3266" id="token-31-3" morph="none" pos="word" start_char="3258">улучшения</TOKEN>
<TOKEN end_char="3279" id="token-31-4" morph="none" pos="word" start_char="3268">клинического</TOKEN>
<TOKEN end_char="3289" id="token-31-5" morph="none" pos="word" start_char="3281">состояния</TOKEN>
<TOKEN end_char="3291" id="token-31-6" morph="none" pos="punct" start_char="3291">(</TOKEN>
<TOKEN end_char="3293" id="token-31-7" morph="none" pos="word" start_char="3292">до</TOKEN>
<TOKEN end_char="3301" id="token-31-8" morph="none" pos="word" start_char="3295">мягкого</TOKEN>
<TOKEN end_char="3312" id="token-31-9" morph="none" pos="word" start_char="3303">проявления</TOKEN>
<TOKEN end_char="3322" id="token-31-10" morph="none" pos="word" start_char="3314">симптомов</TOKEN>
<TOKEN end_char="3326" id="token-31-11" morph="none" pos="word" start_char="3324">или</TOKEN>
<TOKEN end_char="3329" id="token-31-12" morph="none" pos="word" start_char="3328">их</TOKEN>
<TOKEN end_char="3340" id="token-31-13" morph="none" pos="word" start_char="3331">отсутствия</TOKEN>
<TOKEN end_char="3341" id="token-31-14" morph="none" pos="punct" start_char="3341">)</TOKEN>
<TOKEN end_char="3351" id="token-31-15" morph="none" pos="word" start_char="3343">составило</TOKEN>
<TOKEN end_char="3354" id="token-31-16" morph="none" pos="word" start_char="3353">13</TOKEN>
<TOKEN end_char="3359" id="token-31-17" morph="none" pos="word" start_char="3356">дней</TOKEN>
<TOKEN end_char="3361" id="token-31-18" morph="none" pos="word" start_char="3361">в</TOKEN>
<TOKEN end_char="3376" id="token-31-19" morph="none" pos="unknown" start_char="3363">плацебо-группе</TOKEN>
<TOKEN end_char="3377" id="token-31-20" morph="none" pos="punct" start_char="3377">,</TOKEN>
<TOKEN end_char="3379" id="token-31-21" morph="none" pos="word" start_char="3379">8</TOKEN>
<TOKEN end_char="3384" id="token-31-22" morph="none" pos="word" start_char="3381">дней</TOKEN>
<TOKEN end_char="3386" id="token-31-23" morph="none" pos="word" start_char="3386">в</TOKEN>
<TOKEN end_char="3393" id="token-31-24" morph="none" pos="word" start_char="3388">группе</TOKEN>
<TOKEN end_char="3401" id="token-31-25" morph="none" pos="word" start_char="3395">высокой</TOKEN>
<TOKEN end_char="3411" id="token-31-26" morph="none" pos="word" start_char="3403">дозировки</TOKEN>
<TOKEN end_char="3413" id="token-31-27" morph="none" pos="word" start_char="3413">и</TOKEN>
<TOKEN end_char="3415" id="token-31-28" morph="none" pos="word" start_char="3415">6</TOKEN>
<TOKEN end_char="3420" id="token-31-29" morph="none" pos="word" start_char="3417">дней</TOKEN>
<TOKEN end_char="3422" id="token-31-30" morph="none" pos="word" start_char="3422">в</TOKEN>
<TOKEN end_char="3429" id="token-31-31" morph="none" pos="word" start_char="3424">группе</TOKEN>
<TOKEN end_char="3436" id="token-31-32" morph="none" pos="word" start_char="3431">низкой</TOKEN>
<TOKEN end_char="3446" id="token-31-33" morph="none" pos="word" start_char="3438">дозировки</TOKEN>
<TOKEN end_char="3447" id="token-31-34" morph="none" pos="punct" start_char="3447">.</TOKEN>
<TRANSLATED_TEXT>Median time before clinical improvement (mild onset or absence of symptoms) was 13 days in the placebo group, 8 days in the high dose group, and 6 days in the low dose group.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="3573" id="segment-32" start_char="3449">
<ORIGINAL_TEXT>При этом эффект от REGN-COV2 был более выражен для серонегативных пациентов и пациентов с исходно высокой вирусной нагрузкой.</ORIGINAL_TEXT>
<TOKEN end_char="3451" id="token-32-0" morph="none" pos="word" start_char="3449">При</TOKEN>
<TOKEN end_char="3456" id="token-32-1" morph="none" pos="word" start_char="3453">этом</TOKEN>
<TOKEN end_char="3463" id="token-32-2" morph="none" pos="word" start_char="3458">эффект</TOKEN>
<TOKEN end_char="3466" id="token-32-3" morph="none" pos="word" start_char="3465">от</TOKEN>
<TOKEN end_char="3476" id="token-32-4" morph="none" pos="unknown" start_char="3468">REGN-COV2</TOKEN>
<TOKEN end_char="3480" id="token-32-5" morph="none" pos="word" start_char="3478">был</TOKEN>
<TOKEN end_char="3486" id="token-32-6" morph="none" pos="word" start_char="3482">более</TOKEN>
<TOKEN end_char="3494" id="token-32-7" morph="none" pos="word" start_char="3488">выражен</TOKEN>
<TOKEN end_char="3498" id="token-32-8" morph="none" pos="word" start_char="3496">для</TOKEN>
<TOKEN end_char="3513" id="token-32-9" morph="none" pos="word" start_char="3500">серонегативных</TOKEN>
<TOKEN end_char="3523" id="token-32-10" morph="none" pos="word" start_char="3515">пациентов</TOKEN>
<TOKEN end_char="3525" id="token-32-11" morph="none" pos="word" start_char="3525">и</TOKEN>
<TOKEN end_char="3535" id="token-32-12" morph="none" pos="word" start_char="3527">пациентов</TOKEN>
<TOKEN end_char="3537" id="token-32-13" morph="none" pos="word" start_char="3537">с</TOKEN>
<TOKEN end_char="3545" id="token-32-14" morph="none" pos="word" start_char="3539">исходно</TOKEN>
<TOKEN end_char="3553" id="token-32-15" morph="none" pos="word" start_char="3547">высокой</TOKEN>
<TOKEN end_char="3562" id="token-32-16" morph="none" pos="word" start_char="3555">вирусной</TOKEN>
<TOKEN end_char="3572" id="token-32-17" morph="none" pos="word" start_char="3564">нагрузкой</TOKEN>
<TOKEN end_char="3573" id="token-32-18" morph="none" pos="punct" start_char="3573">.</TOKEN>
<TRANSLATED_TEXT>The effect of REGN-COV2 was more pronounced in seronegative patients and patients with baseline high viral load.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="3726" id="segment-33" start_char="3576">
<ORIGINAL_TEXT>Дле серонегативных пациентов риск обращения за медицинской помощью был выше: 10 из 12 обращений случились именно в серонегативной подгруппе участников.</ORIGINAL_TEXT>
<TOKEN end_char="3578" id="token-33-0" morph="none" pos="word" start_char="3576">Дле</TOKEN>
<TOKEN end_char="3593" id="token-33-1" morph="none" pos="word" start_char="3580">серонегативных</TOKEN>
<TOKEN end_char="3603" id="token-33-2" morph="none" pos="word" start_char="3595">пациентов</TOKEN>
<TOKEN end_char="3608" id="token-33-3" morph="none" pos="word" start_char="3605">риск</TOKEN>
<TOKEN end_char="3618" id="token-33-4" morph="none" pos="word" start_char="3610">обращения</TOKEN>
<TOKEN end_char="3621" id="token-33-5" morph="none" pos="word" start_char="3620">за</TOKEN>
<TOKEN end_char="3633" id="token-33-6" morph="none" pos="word" start_char="3623">медицинской</TOKEN>
<TOKEN end_char="3641" id="token-33-7" morph="none" pos="word" start_char="3635">помощью</TOKEN>
<TOKEN end_char="3645" id="token-33-8" morph="none" pos="word" start_char="3643">был</TOKEN>
<TOKEN end_char="3650" id="token-33-9" morph="none" pos="word" start_char="3647">выше</TOKEN>
<TOKEN end_char="3651" id="token-33-10" morph="none" pos="punct" start_char="3651">:</TOKEN>
<TOKEN end_char="3654" id="token-33-11" morph="none" pos="word" start_char="3653">10</TOKEN>
<TOKEN end_char="3657" id="token-33-12" morph="none" pos="word" start_char="3656">из</TOKEN>
<TOKEN end_char="3660" id="token-33-13" morph="none" pos="word" start_char="3659">12</TOKEN>
<TOKEN end_char="3670" id="token-33-14" morph="none" pos="word" start_char="3662">обращений</TOKEN>
<TOKEN end_char="3680" id="token-33-15" morph="none" pos="word" start_char="3672">случились</TOKEN>
<TOKEN end_char="3687" id="token-33-16" morph="none" pos="word" start_char="3682">именно</TOKEN>
<TOKEN end_char="3689" id="token-33-17" morph="none" pos="word" start_char="3689">в</TOKEN>
<TOKEN end_char="3704" id="token-33-18" morph="none" pos="word" start_char="3691">серонегативной</TOKEN>
<TOKEN end_char="3714" id="token-33-19" morph="none" pos="word" start_char="3706">подгруппе</TOKEN>
<TOKEN end_char="3725" id="token-33-20" morph="none" pos="word" start_char="3716">участников</TOKEN>
<TOKEN end_char="3726" id="token-33-21" morph="none" pos="punct" start_char="3726">.</TOKEN>
<TRANSLATED_TEXT>For seronegative patients, the risk of seeking treatment was higher: 10 out of 12 cases occurred in the seronegative subgroup.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="3872" id="segment-34" start_char="3728">
<ORIGINAL_TEXT>15,2% серонегативных пациентов из плацебо-групы, 7,7% из группы высокой дозировки и 4,9% пациентов из группы низкой дозировки обратились к врачу.</ORIGINAL_TEXT>
<TOKEN end_char="3731" id="token-34-0" morph="none" pos="unknown" start_char="3728">15,2</TOKEN>
<TOKEN end_char="3732" id="token-34-1" morph="none" pos="punct" start_char="3732">%</TOKEN>
<TOKEN end_char="3747" id="token-34-2" morph="none" pos="word" start_char="3734">серонегативных</TOKEN>
<TOKEN end_char="3757" id="token-34-3" morph="none" pos="word" start_char="3749">пациентов</TOKEN>
<TOKEN end_char="3760" id="token-34-4" morph="none" pos="word" start_char="3759">из</TOKEN>
<TOKEN end_char="3774" id="token-34-5" morph="none" pos="unknown" start_char="3762">плацебо-групы</TOKEN>
<TOKEN end_char="3775" id="token-34-6" morph="none" pos="punct" start_char="3775">,</TOKEN>
<TOKEN end_char="3779" id="token-34-7" morph="none" pos="unknown" start_char="3777">7,7</TOKEN>
<TOKEN end_char="3780" id="token-34-8" morph="none" pos="punct" start_char="3780">%</TOKEN>
<TOKEN end_char="3783" id="token-34-9" morph="none" pos="word" start_char="3782">из</TOKEN>
<TOKEN end_char="3790" id="token-34-10" morph="none" pos="word" start_char="3785">группы</TOKEN>
<TOKEN end_char="3798" id="token-34-11" morph="none" pos="word" start_char="3792">высокой</TOKEN>
<TOKEN end_char="3808" id="token-34-12" morph="none" pos="word" start_char="3800">дозировки</TOKEN>
<TOKEN end_char="3810" id="token-34-13" morph="none" pos="word" start_char="3810">и</TOKEN>
<TOKEN end_char="3814" id="token-34-14" morph="none" pos="unknown" start_char="3812">4,9</TOKEN>
<TOKEN end_char="3815" id="token-34-15" morph="none" pos="punct" start_char="3815">%</TOKEN>
<TOKEN end_char="3825" id="token-34-16" morph="none" pos="word" start_char="3817">пациентов</TOKEN>
<TOKEN end_char="3828" id="token-34-17" morph="none" pos="word" start_char="3827">из</TOKEN>
<TOKEN end_char="3835" id="token-34-18" morph="none" pos="word" start_char="3830">группы</TOKEN>
<TOKEN end_char="3842" id="token-34-19" morph="none" pos="word" start_char="3837">низкой</TOKEN>
<TOKEN end_char="3852" id="token-34-20" morph="none" pos="word" start_char="3844">дозировки</TOKEN>
<TOKEN end_char="3863" id="token-34-21" morph="none" pos="word" start_char="3854">обратились</TOKEN>
<TOKEN end_char="3865" id="token-34-22" morph="none" pos="word" start_char="3865">к</TOKEN>
<TOKEN end_char="3871" id="token-34-23" morph="none" pos="word" start_char="3867">врачу</TOKEN>
<TOKEN end_char="3872" id="token-34-24" morph="none" pos="punct" start_char="3872">.</TOKEN>
<TRANSLATED_TEXT>15.2% of seronegative patients in the placebo group, 7.7% in the high-dose group, and 4.9% in the low-dose group went to a doctor.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="3934" id="segment-35" start_char="3875">
<ORIGINAL_TEXT>Обе дозы REGN-COV2 продемонстрировали хорошую переносимость.</ORIGINAL_TEXT>
<TOKEN end_char="3877" id="token-35-0" morph="none" pos="word" start_char="3875">Обе</TOKEN>
<TOKEN end_char="3882" id="token-35-1" morph="none" pos="word" start_char="3879">дозы</TOKEN>
<TOKEN end_char="3892" id="token-35-2" morph="none" pos="unknown" start_char="3884">REGN-COV2</TOKEN>
<TOKEN end_char="3911" id="token-35-3" morph="none" pos="word" start_char="3894">продемонстрировали</TOKEN>
<TOKEN end_char="3919" id="token-35-4" morph="none" pos="word" start_char="3913">хорошую</TOKEN>
<TOKEN end_char="3933" id="token-35-5" morph="none" pos="word" start_char="3921">переносимость</TOKEN>
<TOKEN end_char="3934" id="token-35-6" morph="none" pos="punct" start_char="3934">.</TOKEN>
<TRANSLATED_TEXT>Both doses of REGN-COV2 showed good tolerability.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="4054" id="segment-36" start_char="3936">
<ORIGINAL_TEXT>Серьезные побочные эффекты наблюдались у двух пациентов из группы плацебо и одного пациента из группы низкой дозировки.</ORIGINAL_TEXT>
<TOKEN end_char="3944" id="token-36-0" morph="none" pos="word" start_char="3936">Серьезные</TOKEN>
<TOKEN end_char="3953" id="token-36-1" morph="none" pos="word" start_char="3946">побочные</TOKEN>
<TOKEN end_char="3961" id="token-36-2" morph="none" pos="word" start_char="3955">эффекты</TOKEN>
<TOKEN end_char="3973" id="token-36-3" morph="none" pos="word" start_char="3963">наблюдались</TOKEN>
<TOKEN end_char="3975" id="token-36-4" morph="none" pos="word" start_char="3975">у</TOKEN>
<TOKEN end_char="3980" id="token-36-5" morph="none" pos="word" start_char="3977">двух</TOKEN>
<TOKEN end_char="3990" id="token-36-6" morph="none" pos="word" start_char="3982">пациентов</TOKEN>
<TOKEN end_char="3993" id="token-36-7" morph="none" pos="word" start_char="3992">из</TOKEN>
<TOKEN end_char="4000" id="token-36-8" morph="none" pos="word" start_char="3995">группы</TOKEN>
<TOKEN end_char="4008" id="token-36-9" morph="none" pos="word" start_char="4002">плацебо</TOKEN>
<TOKEN end_char="4010" id="token-36-10" morph="none" pos="word" start_char="4010">и</TOKEN>
<TOKEN end_char="4017" id="token-36-11" morph="none" pos="word" start_char="4012">одного</TOKEN>
<TOKEN end_char="4026" id="token-36-12" morph="none" pos="word" start_char="4019">пациента</TOKEN>
<TOKEN end_char="4029" id="token-36-13" morph="none" pos="word" start_char="4028">из</TOKEN>
<TOKEN end_char="4036" id="token-36-14" morph="none" pos="word" start_char="4031">группы</TOKEN>
<TOKEN end_char="4043" id="token-36-15" morph="none" pos="word" start_char="4038">низкой</TOKEN>
<TOKEN end_char="4053" id="token-36-16" morph="none" pos="word" start_char="4045">дозировки</TOKEN>
<TOKEN end_char="4054" id="token-36-17" morph="none" pos="punct" start_char="4054">.</TOKEN>
<TRANSLATED_TEXT>Serious side effects were observed in two patients in the placebo group and one in the low dose group.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="4086" id="segment-37" start_char="4056">
<ORIGINAL_TEXT>Ни один из участников не погиб.</ORIGINAL_TEXT>
<TOKEN end_char="4057" id="token-37-0" morph="none" pos="word" start_char="4056">Ни</TOKEN>
<TOKEN end_char="4062" id="token-37-1" morph="none" pos="word" start_char="4059">один</TOKEN>
<TOKEN end_char="4065" id="token-37-2" morph="none" pos="word" start_char="4064">из</TOKEN>
<TOKEN end_char="4076" id="token-37-3" morph="none" pos="word" start_char="4067">участников</TOKEN>
<TOKEN end_char="4079" id="token-37-4" morph="none" pos="word" start_char="4078">не</TOKEN>
<TOKEN end_char="4085" id="token-37-5" morph="none" pos="word" start_char="4081">погиб</TOKEN>
<TOKEN end_char="4086" id="token-37-6" morph="none" pos="punct" start_char="4086">.</TOKEN>
<TRANSLATED_TEXT>None of the participants were killed.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="4183" id="segment-38" start_char="4089">
<ORIGINAL_TEXT>Данное клиническое испытание представляет собой часть большой программы исследования REGN-COV2.</ORIGINAL_TEXT>
<TOKEN end_char="4094" id="token-38-0" morph="none" pos="word" start_char="4089">Данное</TOKEN>
<TOKEN end_char="4106" id="token-38-1" morph="none" pos="word" start_char="4096">клиническое</TOKEN>
<TOKEN end_char="4116" id="token-38-2" morph="none" pos="word" start_char="4108">испытание</TOKEN>
<TOKEN end_char="4129" id="token-38-3" morph="none" pos="word" start_char="4118">представляет</TOKEN>
<TOKEN end_char="4135" id="token-38-4" morph="none" pos="word" start_char="4131">собой</TOKEN>
<TOKEN end_char="4141" id="token-38-5" morph="none" pos="word" start_char="4137">часть</TOKEN>
<TOKEN end_char="4149" id="token-38-6" morph="none" pos="word" start_char="4143">большой</TOKEN>
<TOKEN end_char="4159" id="token-38-7" morph="none" pos="word" start_char="4151">программы</TOKEN>
<TOKEN end_char="4172" id="token-38-8" morph="none" pos="word" start_char="4161">исследования</TOKEN>
<TOKEN end_char="4182" id="token-38-9" morph="none" pos="unknown" start_char="4174">REGN-COV2</TOKEN>
<TOKEN end_char="4183" id="token-38-10" morph="none" pos="punct" start_char="4183">.</TOKEN>
<TRANSLATED_TEXT>This clinical trial is part of a large program of study REGN-COV2.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="4251" id="segment-39" start_char="4185">
<ORIGINAL_TEXT>По плану в исследовании должны принять участие более 2 000 человек.</ORIGINAL_TEXT>
<TOKEN end_char="4186" id="token-39-0" morph="none" pos="word" start_char="4185">По</TOKEN>
<TOKEN end_char="4192" id="token-39-1" morph="none" pos="word" start_char="4188">плану</TOKEN>
<TOKEN end_char="4194" id="token-39-2" morph="none" pos="word" start_char="4194">в</TOKEN>
<TOKEN end_char="4207" id="token-39-3" morph="none" pos="word" start_char="4196">исследовании</TOKEN>
<TOKEN end_char="4214" id="token-39-4" morph="none" pos="word" start_char="4209">должны</TOKEN>
<TOKEN end_char="4222" id="token-39-5" morph="none" pos="word" start_char="4216">принять</TOKEN>
<TOKEN end_char="4230" id="token-39-6" morph="none" pos="word" start_char="4224">участие</TOKEN>
<TOKEN end_char="4236" id="token-39-7" morph="none" pos="word" start_char="4232">более</TOKEN>
<TOKEN end_char="4238" id="token-39-8" morph="none" pos="word" start_char="4238">2</TOKEN>
<TOKEN end_char="4242" id="token-39-9" morph="none" pos="word" start_char="4240">000</TOKEN>
<TOKEN end_char="4250" id="token-39-10" morph="none" pos="word" start_char="4244">человек</TOKEN>
<TOKEN end_char="4251" id="token-39-11" morph="none" pos="punct" start_char="4251">.</TOKEN>
<TRANSLATED_TEXT>More than 2,000 people are expected to participate in the study.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="4457" id="segment-40" start_char="4253">
<ORIGINAL_TEXT>В частности, для фазы 2/3 испытаний будут набраны 1 300 пациентов, наблюдение за участниками продолжится в течение 29 дней с оценкой вирусной нагрузки в верхнем отделе респираторного тракта каждые 2–3 дня.</ORIGINAL_TEXT>
<TOKEN end_char="4253" id="token-40-0" morph="none" pos="word" start_char="4253">В</TOKEN>
<TOKEN end_char="4263" id="token-40-1" morph="none" pos="word" start_char="4255">частности</TOKEN>
<TOKEN end_char="4264" id="token-40-2" morph="none" pos="punct" start_char="4264">,</TOKEN>
<TOKEN end_char="4268" id="token-40-3" morph="none" pos="word" start_char="4266">для</TOKEN>
<TOKEN end_char="4273" id="token-40-4" morph="none" pos="word" start_char="4270">фазы</TOKEN>
<TOKEN end_char="4277" id="token-40-5" morph="none" pos="unknown" start_char="4275">2/3</TOKEN>
<TOKEN end_char="4287" id="token-40-6" morph="none" pos="word" start_char="4279">испытаний</TOKEN>
<TOKEN end_char="4293" id="token-40-7" morph="none" pos="word" start_char="4289">будут</TOKEN>
<TOKEN end_char="4301" id="token-40-8" morph="none" pos="word" start_char="4295">набраны</TOKEN>
<TOKEN end_char="4303" id="token-40-9" morph="none" pos="word" start_char="4303">1</TOKEN>
<TOKEN end_char="4307" id="token-40-10" morph="none" pos="word" start_char="4305">300</TOKEN>
<TOKEN end_char="4317" id="token-40-11" morph="none" pos="word" start_char="4309">пациентов</TOKEN>
<TOKEN end_char="4318" id="token-40-12" morph="none" pos="punct" start_char="4318">,</TOKEN>
<TOKEN end_char="4329" id="token-40-13" morph="none" pos="word" start_char="4320">наблюдение</TOKEN>
<TOKEN end_char="4332" id="token-40-14" morph="none" pos="word" start_char="4331">за</TOKEN>
<TOKEN end_char="4344" id="token-40-15" morph="none" pos="word" start_char="4334">участниками</TOKEN>
<TOKEN end_char="4356" id="token-40-16" morph="none" pos="word" start_char="4346">продолжится</TOKEN>
<TOKEN end_char="4358" id="token-40-17" morph="none" pos="word" start_char="4358">в</TOKEN>
<TOKEN end_char="4366" id="token-40-18" morph="none" pos="word" start_char="4360">течение</TOKEN>
<TOKEN end_char="4369" id="token-40-19" morph="none" pos="word" start_char="4368">29</TOKEN>
<TOKEN end_char="4374" id="token-40-20" morph="none" pos="word" start_char="4371">дней</TOKEN>
<TOKEN end_char="4376" id="token-40-21" morph="none" pos="word" start_char="4376">с</TOKEN>
<TOKEN end_char="4384" id="token-40-22" morph="none" pos="word" start_char="4378">оценкой</TOKEN>
<TOKEN end_char="4393" id="token-40-23" morph="none" pos="word" start_char="4386">вирусной</TOKEN>
<TOKEN end_char="4402" id="token-40-24" morph="none" pos="word" start_char="4395">нагрузки</TOKEN>
<TOKEN end_char="4404" id="token-40-25" morph="none" pos="word" start_char="4404">в</TOKEN>
<TOKEN end_char="4412" id="token-40-26" morph="none" pos="word" start_char="4406">верхнем</TOKEN>
<TOKEN end_char="4419" id="token-40-27" morph="none" pos="word" start_char="4414">отделе</TOKEN>
<TOKEN end_char="4434" id="token-40-28" morph="none" pos="word" start_char="4421">респираторного</TOKEN>
<TOKEN end_char="4441" id="token-40-29" morph="none" pos="word" start_char="4436">тракта</TOKEN>
<TOKEN end_char="4448" id="token-40-30" morph="none" pos="word" start_char="4443">каждые</TOKEN>
<TOKEN end_char="4452" id="token-40-31" morph="none" pos="unknown" start_char="4450">2–3</TOKEN>
<TOKEN end_char="4456" id="token-40-32" morph="none" pos="word" start_char="4454">дня</TOKEN>
<TOKEN end_char="4457" id="token-40-33" morph="none" pos="punct" start_char="4457">.</TOKEN>
<TRANSLATED_TEXT>In particular, 1,300 patients will be recruited for phase 2 / 3 of the test, participants will continue to be monitored for 29 days with an assessment of viral load in the upper respiratory tract every 2-3 days.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="4680" id="segment-41" start_char="4460">
<ORIGINAL_TEXT>REGN-COV2 также испытывается в фазе 2/3 клинических испытаний терапии для госпитализированных пациентов с COVID-19, фазе 3 программы RECOVERY и фазе 3 испытаний препаратов для профилактики COVID-19 у контактных индивидов.</ORIGINAL_TEXT>
<TOKEN end_char="4468" id="token-41-0" morph="none" pos="unknown" start_char="4460">REGN-COV2</TOKEN>
<TOKEN end_char="4474" id="token-41-1" morph="none" pos="word" start_char="4470">также</TOKEN>
<TOKEN end_char="4487" id="token-41-2" morph="none" pos="word" start_char="4476">испытывается</TOKEN>
<TOKEN end_char="4489" id="token-41-3" morph="none" pos="word" start_char="4489">в</TOKEN>
<TOKEN end_char="4494" id="token-41-4" morph="none" pos="word" start_char="4491">фазе</TOKEN>
<TOKEN end_char="4498" id="token-41-5" morph="none" pos="unknown" start_char="4496">2/3</TOKEN>
<TOKEN end_char="4510" id="token-41-6" morph="none" pos="word" start_char="4500">клинических</TOKEN>
<TOKEN end_char="4520" id="token-41-7" morph="none" pos="word" start_char="4512">испытаний</TOKEN>
<TOKEN end_char="4528" id="token-41-8" morph="none" pos="word" start_char="4522">терапии</TOKEN>
<TOKEN end_char="4532" id="token-41-9" morph="none" pos="word" start_char="4530">для</TOKEN>
<TOKEN end_char="4552" id="token-41-10" morph="none" pos="word" start_char="4534">госпитализированных</TOKEN>
<TOKEN end_char="4562" id="token-41-11" morph="none" pos="word" start_char="4554">пациентов</TOKEN>
<TOKEN end_char="4564" id="token-41-12" morph="none" pos="word" start_char="4564">с</TOKEN>
<TOKEN end_char="4573" id="token-41-13" morph="none" pos="unknown" start_char="4566">COVID-19</TOKEN>
<TOKEN end_char="4574" id="token-41-14" morph="none" pos="punct" start_char="4574">,</TOKEN>
<TOKEN end_char="4579" id="token-41-15" morph="none" pos="word" start_char="4576">фазе</TOKEN>
<TOKEN end_char="4581" id="token-41-16" morph="none" pos="word" start_char="4581">3</TOKEN>
<TOKEN end_char="4591" id="token-41-17" morph="none" pos="word" start_char="4583">программы</TOKEN>
<TOKEN end_char="4600" id="token-41-18" morph="none" pos="word" start_char="4593">RECOVERY</TOKEN>
<TOKEN end_char="4602" id="token-41-19" morph="none" pos="word" start_char="4602">и</TOKEN>
<TOKEN end_char="4607" id="token-41-20" morph="none" pos="word" start_char="4604">фазе</TOKEN>
<TOKEN end_char="4609" id="token-41-21" morph="none" pos="word" start_char="4609">3</TOKEN>
<TOKEN end_char="4619" id="token-41-22" morph="none" pos="word" start_char="4611">испытаний</TOKEN>
<TOKEN end_char="4630" id="token-41-23" morph="none" pos="word" start_char="4621">препаратов</TOKEN>
<TOKEN end_char="4634" id="token-41-24" morph="none" pos="word" start_char="4632">для</TOKEN>
<TOKEN end_char="4647" id="token-41-25" morph="none" pos="word" start_char="4636">профилактики</TOKEN>
<TOKEN end_char="4656" id="token-41-26" morph="none" pos="unknown" start_char="4649">COVID-19</TOKEN>
<TOKEN end_char="4658" id="token-41-27" morph="none" pos="word" start_char="4658">у</TOKEN>
<TOKEN end_char="4669" id="token-41-28" morph="none" pos="word" start_char="4660">контактных</TOKEN>
<TOKEN end_char="4679" id="token-41-29" morph="none" pos="word" start_char="4671">индивидов</TOKEN>
<TOKEN end_char="4680" id="token-41-30" morph="none" pos="punct" start_char="4680">.</TOKEN>
<TRANSLATED_TEXT>REGN-COV2 is also tested in phase 2 / 3 clinical trials of treatment for hospitalized patients with COVID-19, phase 3 of the RECOVERY program and phase 3 trials of drugs for the prevention of COVID-19 in contact individuals.</TRANSLATED_TEXT><DETECTED_LANGUAGE>ru</DETECTED_LANGUAGE></SEG>
<SEG end_char="4690" id="segment-42" start_char="4683">
<ORIGINAL_TEXT>Источник</ORIGINAL_TEXT>
<TOKEN end_char="4690" id="token-42-0" morph="none" pos="word" start_char="4683">Источник</TOKEN>
<TRANSLATED_TEXT>Source</TRANSLATED_TEXT><DETECTED_LANGUAGE>mk</DETECTED_LANGUAGE></SEG>
</TEXT>
</DOC>
</LCTL_TEXT>